MyFinsight
Home
Blog
About
Contact
Download
Download image
Redemption of term deposits
$74,427K
Net cash provided
by/(used in) investing...
$10,000K
Canceled cashflow
$64,427K
Decrease in cash and cash
equivalents
-$5,603K
Canceled cashflow
$10,000K
Share-based compensation
expense
$2,447K
Decrease/(increase) in other current
assets
-$931K
Depreciation expense
$72K
Amortization expense
$34K
Purchase of term deposits
$64,427K
Net cash used in
operations
-$15,603K
Canceled cashflow
$3,484K
General and
administrative expenses
-$11,584K
Cost of sales
-$192K
Tax expense
-$11K
Net loss
-$14,957K
(decrease)/increase in trade and
other payables
-$2,949K
Canceled cashflow
$11,787K
Other income, net
$519K
Increase in contract
liabilities
-$404K
(increase)/decrease in r&d benefit
receivable
$209K
Net foreign
exchange impacts
$25K
Increase in operating
lease liabilities
-$24K
something is missing
-$26,641K
Revenue
-$103K
Back
Back
Cash Flow
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)
source: myfinsight.com